

Evaluation summary  
Survey of 20 May 2022

651

**Immunophenotyping 04 - Cellular Immunodeficiency Diagnostic**

Lymphocytes (/μl, N = 18)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	1831	1282	-	2380	1831	8.52	18	94.4	88.9
	32	1513	1059	-	1967	1513	8.99	18	94.4	

Rate of success: 88,9%

CD18 on Lymphocytes (% of lymphocytes) (% , N = 1)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	96.9	67.8	-	100	96.9	0.000	1		
	32	96.1	67.3	-	100	96.1	0.000	1		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

HLA-DR on Lymphocytes (% of lymphocytes) (% , N = 7)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	29.5	17.4	-	41.6	29.5	29.0	7		
	32	31.5	18.6	-	44.4	31.5	29.0	7		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 71,4%

T-Cells (/μl, N = 21)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	1305	913	-	1697	1305	8.89	21	100	90.5
	32	862	603	-	1121	862	8.36	21	90.5	

Rate of success: 90,5%

alpha/beta T-Cells (% of CD3+) (% , N = 15)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	87.7	61.4	-	100	87.7	1.00	15	100	86.7
	32	94.2	65.9	-	100	94.2	0.729	15	86.7	

Rate of success: 86,7%

gamma/delta T-Cells (% of CD3+) (% , N = 17)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	11.8	8.26	-	15.3	11.8	6.39	17	94.1	88.2
	32	5.35	3.74	-	6.96	5.35	11.3	17	88.2	

Rate of success: 88,2%

activated T-Cells (HLA-DR+) (% of CD3+) (% , N = 16)										
Collective	Sam-ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	10.7	4.79	-	16.6	10.7	59.0	16	75.0	68.8
	32	7.36	3.97	-	10.8	7.36	49.3	16	81.3	

Rate of success: 68,8%

CD3+CD45RA+CD45RO- (% of CD3+) (% , N = 6)										
Collective	Sam-ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	37.9	26.5	-	49.3	37.9	21.7	6		
	32	32.9	23.0	-	42.8	32.9	19.9	6		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 83,3%

CD3+CD45RA+CD45RO+ (% of CD3+) (% , N = 5)										
Collective	Sam-ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	22.5	15.7	-	29.3	22.5	47.1	5		
	32	28.3	19.8	-	36.8	28.3	56.2	5		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 40%

CD3+CD45RA-CD45RO+ (% of CD3+) (% , N = 6)										
Collective	Sam-ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	45.2	18.9	-	71.5	45.2	38.1	6		
	32	49.4	27.2	-	71.6	49.4	29.4	6		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

DNTs (CD4- CD8- CD3+ TCRa/b +) (% of CD3+) (% , N = 15)										
Collective	Sam-ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	2.18	0.176	-	4.18	2.18	95.0	15	80.0	73.3
	32	2.49	1.49	-	3.49	2.49	41.4	15	73.3	

Rate of success: 73,3%

T-Helper Cells (/μl, N = 21)										
Collective	Sam-ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	671	470	-	872	671	10.7	21	90.5	85.7
	32	681	477	-	885	681	9.79	21	90.5	

Rate of success: 85,7%

T-Cells (CD3+/CD4+) - naive (% of CD3+CD4+) (% , N = 18)										
Collective	Sam-ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	27.6	19.3	-	35.9	27.6	16.5	18	88.9	83.3
	32	32.1	22.5	-	41.7	32.1	17.4	18	83.3	

Rate of success: 83,3%

<b>central memory T-Helper Cells (% of CD3+CD4+) (% , N = 15)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	50.8	35.6	-	66.0	50.8	17.8	15	93.3	80.0
	32	46.7	32.7	-	60.7	46.7	23.1	15	80.0	

Rate of success: 80%

<b>effector memory T-Helper Cells (% of CD3+CD4+) (% , N = 15)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	18.5	8.63	-	28.4	18.5	55.1	15	66.7	60.0
	32	17.4	4.80	-	30.0	17.4	74.7	15	66.7	

Rate of success: 60%

<b>effector T-Helper Cells (% of CD3+CD4+) (% , N = 14)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	0.692	0.215	-	1.17	0.692	68.6	14	64.3	57.1
	32	1.02	0.165	-	1.88	1.02	83.7	14	78.6	

Rate of success: 57,1%

<b>memory T-Helper Cells (total) (% of CD3+CD4+) (% , N = 15)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	70.6	49.4	-	91.8	70.6	9.46	15	93.3	86.7
	32	64.0	44.8	-	83.2	64.0	13.6	15	86.7	

Rate of success: 86,7%

<b>activated T-Helper Cells (% of CD3+CD4+) (% , N = 15)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	7.87	4.51	-	11.2	7.87	44.2	15	80.0	66.7
	32	6.14	3.15	-	9.13	6.14	50.3	15	66.7	

Rate of success: 66,7%

<b>RTE T-Helper Cells (% of CD3+CD4+) (% , N = 13)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	21.5	14.9	-	28.1	21.5	29.3	13	69.2	69.2
	32	17.7	11.5	-	23.9	17.7	33.8	13	76.9	

Rate of success: 69,2%

<b>regulatory T-Cells (CD25/127) (% of CD3+CD4+) (% , N = 12)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	6.04	4.23	-	7.85	6.04	23.5	12	83.3	83.3
	32	6.82	4.77	-	8.87	6.82	17.6	12	100	

Rate of success: 83,3%

regulatory T-Cells (with FoxP3) (% of CD3+CD4+) (% , N = 4)										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	4.40	2.15	-	6.65	4.40	27.3	4		
	32	3.82	2.67	-	4.97	3.82	10.1	4		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

TH1-Cells (Surrogat marker) (% of memory-TH) (% , N = 6)										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	19.1	8.00	-	29.0	19.1	74.3	6		
	32	18.5	6.00	-	30.0	18.5	83.8	6		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 50%

TH2-Cells (Surrogat marker) (% of memory-TH) (% , N = 6)										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	9.70	5.00	-	17.0	9.70	75.9	6		
	32	10.9	6.00	-	19.0	10.9	79.0	6		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 66,7%

TH17-Cells (Surrogat marker) (% of memory-TH) (% , N = 6)										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	15.9	0.690	-	31.1	15.9	62.5	6		
	32	13.3	0.040	-	26.6	13.3	65.2	6		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

TH1-Cells (with intracellular cytokines) (% of memory-TH) (% , N = 1)										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	22.4	15.7	-	29.1	22.4	0.000	1		
	32	29.4	20.6	-	38.2	29.4	0.000	1		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

cytotoxic T-Cells (/μl, N = 21)										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	495	347	-	644	495	11.0	21	90.5	85.7
	32	129	90.3	-	168	129	11.3	21	90.5	

Rate of success: 85,7%

cytotoxic T-Cells selective (/μl, N = 1)										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	473	331	-	615	473	0.000	1		
	32	95.0	66.5	-	124	95.0	0.000	1		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

<b>naive cytotoxic T-Cells (% of CD3+CD8+) (% , N = 17)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	7.61	4.40	-	10.8	7.61	46.5	17	70.6	70.6
	32	46.1	32.3	-	59.9	46.1	11.5	17	88.2	

Rate of success: 70,6%

<b>cytotoxic central memory T-Cells (% of CD3+CD8+) (% , N = 16)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	14.9	1.49	-	28.3	14.9	96.0	16	68.8	62.5
	32	22.2	6.06	-	38.3	22.2	77.5	16	62.5	

Rate of success: 62,5%

<b>cytotoxic effector memory T-Cells (% of CD3+CD8+) (% , N = 15)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	34.3	19.8	-	48.8	34.3	43.7	15	66.7	60.0
	32	22.5	6.42	-	38.6	22.5	73.8	15	66.7	

Rate of success: 60%

<b>cytotoxic effector T-Cells (% of CD3+CD8+) (% , N = 14)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	43.0	30.1	-	55.9	43.0	14.6	14	100	71.4
	32	7.78	1.87	-	13.7	7.78	75.8	14	71.4	

Rate of success: 71,4%

<b>cytotoxic memory T-Cells (total) (% of CD3+CD8+) (% , N = 9)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	47.9	33.5	-	62.3	47.9	19.4	9	88.9	88.9
	32	44.2	30.9	-	57.5	44.2	19.2	9	100	

Rate of success: 88,9%

<b>activated cytotoxic T-Cells (% of CD3+CD8+) (% , N = 14)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	15.2	5.24	-	25.2	15.2	65.4	14	71.4	64.3
	32	13.9	7.42	-	20.4	13.9	46.5	14	71.4	

Rate of success: 64,3%

<b>B-Cells (/μl, N = 21)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	361	253	-	469	361	13.2	21	95.2	95.2
	32	379	265	-	493	379	12.3	21	100	

Rate of success: 95,2%

<b>B-Cells (transitional) (% of CD19+) (% , N = 15)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	4.25	0.920	-	7.58	4.25	81.2	15	80.0	66.7
	32	2.82	0.660	-	4.98	2.82	79.1	15	73.3	

Rate of success: 66,7%

<b>B-Cells (naive) (% of CD19+) (% , N = 18)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	80.2	56.1	-	100	80.2	5.54	18	100	100
	32	69.4	48.6	-	90.2	69.4	10.1	18	100	

Rate of success: 100%

<b>B-Cells (memory) (% of CD19+) (% , N = 17)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	15.9	11.1	-	20.7	15.9	26.9	17	76.5	70.6
	32	21.9	15.3	-	28.5	21.9	24.9	17	82.4	

Rate of success: 70,6%

<b>B-Cells (non-switched memory) (% of CD19+) (% , N = 20)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	8.55	5.99	-	11.1	8.55	23.3	20	80.0	60.0
	32	8.80	6.16	-	11.4	8.80	27.4	20	70.0	

Rate of success: 60%

<b>B-Cells (switched memory) (% of CD19+) (% , N = 20)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	6.67	4.20	-	9.14	6.67	44.1	20	60.0	45.0
	32	12.1	8.47	-	15.7	12.1	33.6	20	70.0	

Rate of success: 45%

<b>B-Cells (IgM only) (% of CD19+) (% , N = 10)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	1.18	0.000	-	2.63	1.18	103	10	80.0	80.0
	32	1.40	0.000	-	2.95	1.40	93.6	10	80.0	

Rate of success: 80%

<b>B-Cells (IgA+) (% of CD19+) (% , N = 4)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	(1) 31	3.36	0.180	-	6.54	3.36	50.3	4		
	32	6.55	4.15	-	8.95	6.55	19.5	4		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

<b>B-Cells (IgG+) (% of CD19+) (% , N = 4)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	4.76	3.33	-	6.19	4.76	13.5	4		
	32	7.92	5.54	-	10.3	7.92	8.03	4		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

<b>B-Cells CD21/CD38 low (activated) (% of CD19+) (% , N = 13)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	1.48	0.655	-	2.31	1.48	53.6	13	76.9	69.2
	32	3.51	1.75	-	5.27	3.51	48.1	13	84.6	

Rate of success: 69,2%

<b>Plasmablasts (% of CD19+) (% , N = 13)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	0.200	0.029	-	0.371	0.200	82.5	13	76.9	61.5
	32	0.255	0.063	-	0.500	0.255	72.5	13	76.9	

Rate of success: 61,5%

<b>non-switched Plasmablasts (% of CD19+) (% , N = 2)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	0.050	0.035	-	0.065	0.050	160	2		
	32	0.000	0.000	-	0.000	0.000		2		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 0%

<b>switched Plasmablasts (% of CD19+) (% , N = 3)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	0.300	0.210	-	0.390	0.300	100	3		
	32	0.200	0.140	-	0.260	0.200	0.000	3		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 0%

<b>Plasma cells (/μl, N = 3)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	0.336	0.235	-	0.437	0.336	104	3		
	32	0.000	0.000	-	0.000	0.000		3		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 33,3%

<b>NK-Cells (/μl, N = 21)</b>										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	167	117	-	217	167	17.7	21	90.5	90.5
	32	239	167	-	311	239	15.4	21	90.5	

Rate of success: 90,5%

<b>NK)p30+ NK-Cells (% of NK) (% , N = 1)</b>										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	26.7	18.7	-	34.7	26.7	0.000	1		
	32	72.4	50.7	-	94.1	72.4	0.000	1		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

<b>NK)p44+ NK-Cells (% of NK) (% , N = 1)</b>										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	1.90	1.33	-	2.47	1.90	0.000	1		
	32	1.10	0.770	-	1.43	1.10	0.000	1		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

<b>NK)p46+ NK-Cells (% of NK) (% , N = 1)</b>										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	41.8	29.3	-	54.3	41.8	0.000	1		
	32	68.3	47.8	-	88.8	68.3	0.000	1		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

<b>cytolytic NK-Cells (% of NK) (% , N = 2)</b>										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	36.8	25.8	-	47.8	36.8	71.7	2		
	32	19.5	13.7	-	25.4	19.5	51.0	2		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 0%

<b>regulatory NK-Cells (CD56bright) (% of NK) (% , N = 4)</b>										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	6.78	4.75	-	8.81	6.78	75.7	4		
	32	3.34	2.34	-	4.34	3.34	66.8	4		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 25%

<b>NKT-like-Cells (/μl, N = 10)</b>										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	31	134	83.0	-	196	134	85.8	10	40.0	30.0
	32	9.32	5.00	-	15.0	9.32	79.7	10	50.0	

Rate of success: 30%

<b>Monocytes (/μl, N = 7)</b>										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	406	284	-	528	406	18.8	7		
	32	580	406	-	754	580	19.8	7		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 71,4%



classical Monocytes (/μl, N = 3)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	433	303	-	563	433	37.4	3		
	32	620	434	-	806	620	7.39	3		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 66,7%

non-classical Monocytes (/μl, N = 2)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	73.4	51.4	-	95.4	73.4	37.9	2		
	32	80.0	56.0	-	104	80.0	64.1	2		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 0%

Granulocytes (/μl, N = 5)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	3172	2220	-	4124	3172	14.1	5		
	32	3520	2464	-	4576	3520	15.1	5		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 80%

CD11a on Granulocytes (% of granulocytes) (% , N = 1)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	97.4	68.2	-	100	97.4	0.000	1		
	32	99.8	69.9	-	100	99.8	0.000	1		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

CD18 on Granulocytes (% of granulocytes) (% , N = 2)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all (1)	31	95.1	66.6	-	100	95.1	5.14	2		
	32	95.0	66.5	-	100	95.0	8.36	2		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 100%

651

## Immunophenotyping 04 - Cellular Immunodeficiency Diagnostic

### Evaluation of T-Helper Cells (N = 15, Rate of success: 100%)

#### Sample 31

Collective	normal (2)	total
all	15 ●	15

#### Sample 32

Collective	normal (2)	total
all	15 ●	15

The point corresponds to the correct result



## Evaluation of cytotoxic T-Cells (N = 15, Rate of success: 80%)

Sample 31

Collective	pathological (1)	normal (2)	total
all	1	14 ●	15

The point corresponds to the correct result

Sample 32

Collective	pathological (1)	normal (2)	total
all	13 ●	2	15

## Evaluation of T-Helper cell subtypes (N = 10, Rate of success: 100%)

Sample 31

Collective	normal (2)	total
all	10 ●	10

The point corresponds to the correct result

Sample 32

Collective	normal (2)	total
all	10 ●	10

## Evaluation of T-Helper cell formation (N = 12, Rate of success: 100%)

Sample 31

Collective	normal (2)	total
all	12 ●	12

The point corresponds to the correct result

Sample 32

Collective	normal (2)	total
all	12 ●	12

## Evaluation of regulatory T-Helper Cells (N = 11, Rate of success: 100%)

Sample 31

Collective	normal (2)	total
all	11 ●	11

The point corresponds to the correct result

Sample 32

Collective	normal (2)	total
all	11 ●	11

## Evaluation of cytotoxic T cell formation (N = 9, Rate of success: 77,8%)

Sample 31

Collective	pathological (1)	normal (2)	total
all	2	7 ●	9

The point corresponds to the correct result

Sample 32

Collective	pathological (1)	normal (2)	total
all	1	8 ●	9

## Evaluation of B cell maturation (N = 15, Rate of success: 66,7%)

Sample 31

Collective	pathological (1)	normal (2)	total
all	5	10 ●	15

The point corresponds to the correct result

Sample 32

Collective	normal (2)	total
all	15 ●	15